CORT — CORCEPT THERAPEUTICS INC catalysts
Next verified catalyst
2026-08-01 — Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecologic · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-08 (month) in 1mo
ESTIMATED |
READOUT
Relacorilant in Combination With Different Treatment Regimens in Patients With G
Phase 2 · Ovarian Cancer, Fallopian Tube Cancer |
CORT CORCEPT THERAPEUTICS INC | Relacorilant 150 mg once daily (QD), Nab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-09 (month) in 2mo
ESTIMATED |
READOUT
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic St
Phase 2 · Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH) |
CORT CORCEPT THERAPEUTICS INC | Miricorilant (Cohort A), Miricorilant (C |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-09 (month) in 2mo
ESTIMATED |
READOUT
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced
Phase 1/2 · Neoplasms |
CORT CORCEPT THERAPEUTICS INC | Nenocorilant 200 mg, Nenocorilant 300 mg |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-10 (month) in 3mo
ESTIMATED |
READOUT
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
Phase 2 · Amyotrophic Lateral Sclerosis |
CORT CORCEPT THERAPEUTICS INC | Dazucorilant 300 mg, Dazucorilant 150 mg |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|